L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
 - EconoTimes)
NEW ORLEANS, March 03, 2017 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., reminds investors that they have until March 13, 2017 to file lead plaintiff applications in a securities class action lawsuit against Ophthotech Corporation (Nasdaq:OPHT), if they purchased the Company’s shares between May 11, 2015 and December 12, 2016, inclusive (the “Class Period”). The action is pending in United States District Court for the Southern District of New York.
What You May Do
If you purchased shares of Ophthotech and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by March 13, 2017.
About the Lawsuit
Ophthotech and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The complaint alleges that Ophthotech made overtly positive representations about the effectiveness and potential of its treatment Fovista when used in combination with Lucentis, a commercially available anti-vascular endothelial growth factor agent, despite awareness that the phase 3 clinical trial of Fovista would fail to achieve its primary endpoint.
On December 12, 2016, Ophthotech announced that the trial had failed to achieve its primary endpoint, and that Fovista and Lucentis demonstrated a non-statistically significant improvement over patients only receiving Lucentis.
On this news, the price of Ophthotech’s shares plummeted.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
